Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.33 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887521 | 0.93 | CA2 (0.48) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15057676 | 0.84 | PAOX (0.47) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL13655625 | 0.84 | CASP2 (0.55) | CA2CA9MEN1KMT2ACASP2 | |
| SCHEMBL28869082 | 0.84 | KDM4E (0.55) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23120734 | 0.83 | IDUA (0.39) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16014560 | 0.83 | CA2 (0.47) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL15131930 | 0.83 | NAAA (0.54) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16345817 | 0.82 | CA2 (0.43) | CA2CA9ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23353390 | 0.82 | CASP2 (0.52) | CA2CA9MEN1KMT2ACASP2 | |
| SCHEMBL28099596 | 0.82 | CA2 (0.47) | CA2CA9ALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793947-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2021-02-03 | — | — | EP | disclosed |
| US-10675359-B2 | Enzymatic conjugation of antibodies | INNATE PHARMA (FR) | 2020-06-09 | — | — | US | disclosed |
| EP-3564259-A2 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2019-11-06 | — | — | EP | disclosed |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | INNATE PHARMA (FR) | 2019-10-08 | — | — | US | disclosed |
| EP-2872894-B1 | SCREENING OF CONJUGATED ANTIBODIES | INNATE PHARMA (FR) | 2019-04-17 | — | — | EP | disclosed |
| EP-3240573-B1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2019-03-20 | — | — | EP | disclosed |
| US-10132799-B2 | Screening of conjugated antibodies | INNATE PHARMA (FR) | 2018-11-20 | — | — | US | disclosed |
| EP-2793949-B1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | INNATE PHARMA (FR) | 2018-07-31 | — | — | US | disclosed |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2018-07-12 | — | — | US | disclosed |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | ARARIS BIOTECH LTD (CH) | 2015-10-08 | — | — | US | disclosed |
| EP-2916872-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | Innate Pharma (FR) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014202775-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| EP-2793949-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| EP-2793947-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | Innate Pharma (FR) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014072482-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2014-05-15 | — | — | WO | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| WO-2013092983-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092998-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10675359-B2 | Enzymatic conjugation of antibodies | DNPEP, MPO, FCGR3B | CA2 1549/4885CA9 604/4885ALDH1A1 161/4885 |
| US-20180193476-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | CA2 1549/4885CA9 604/4885ALDH1A1 161/4885 |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | CA2 2001/4885CA9 855/4885ALDH1A1 484/4885 |
| US-10434180-B2 | Enzymatic conjugation of polypeptides | DNPEP, ENPEP, PEPD | CA2 1953/4885CA9 806/4885ALDH1A1 415/4885 |
| US-10132799-B2 | Screening of conjugated antibodies | FCGR2A, TGM2, TGM6 | CA2 2271/4885CA9 1201/4885ALDH1A1 2044/4885 |
| US-10036010-B2 | Recognition tags for TGase-mediated conjugation | TGM2, TGM3, TGM6 | CA2 1411/4885CA9 525/4885ALDH1A1 3578/4885 |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | CA2 1549/4885CA9 604/4885ALDH1A1 161/4885 |
| US-20150284713-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | TGM2, TGM3, TGM6 | CA2 1411/4885CA9 525/4885ALDH1A1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.